Logo

Integra LifeSciences to Acquire Acclarent for ~$280M

Share this
Acclarent

M&A

Integra LifeSciences to Acquire Acclarent for ~$280M

Shots:

  • Integra LifeSciences has entered into a definitive agreement to acquire Acclarent from Ethicon, an integral part of Johnson & Johnson MedTech company, for $275M in cash (subject to customary purchase price adjustments) in addition to $5M regulatory milestones. The transaction is expected to close by Q2’24
  • Integra expects to enhance its global presence in the ENT market by acquiring Acclarent for its expertise in ENT devices with a portfolio comprising many ENT products & technologies. The collaboration also expects to potentiate collaborations between ENT & neurosurgeons
  • Acclarent ENT portfolio comprises balloon technologies for sinus dilation and eustachian tube dilation along with surgical navigation systems

Ref: GE HealthCare  Image: GE HealthCare 

Related News:- GE HealthCare and AirStrip Signs a Joint Commercialization Agreement for Integrated Patient Monitoring and Cardiac Data Visualization

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Kritika Jha

Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions